miltefosine has been researched along with HIV in 5 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One hundred and fifty patients aged ≥18 years with serologically confirmed HIV and parasitologically confirmed VL were randomly allocated to 1 of 2 treatment arms, either a total 40 mg/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) administered in 8 equal doses over 24 days or a total 30 mg/kg intravenous AmBisome administered in 6 equal doses given concomitantly with a total 1." | 5.51 | AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. ( Alexander, N; Alves, F; Burza, S; Das, P; Das, VNR; de Lima Pereira, A; Gill, N; Goyal, V; Harshana, A; Kazmi, S; Kumar, D; Kumar, V; Lal, CS; Lasry, E; Mahajan, R; Pandey, K; Rewari, B; Rijal, S; Verma, N, 2022) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 5.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Embedded in a clinical trial in Northwest Ethiopia, RNA-Seq was performed on whole blood samples of 28 VL-HIV patients before and after completion of a 29-day treatment regimen of AmBisome or AmBisome/miltefosine." | 5.34 | Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV. ( Adriaensen, W; Alves, F; Blesson, S; Cnops, L; Cordero, CF; Cuypers, B; Diro, E; Kaye, PM; Mengasha, B; van Griensven, J, 2020) |
| "Miltefosine was extracted from DBS samples using a simple method of pretreatment with methanol, resulting in >97% recovery." | 2.82 | Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection. ( Beijnen, JH; Blesson, S; Diro, E; Dorlo, TP; Hailu, A; Hillebrand, MJ; Kip, AE; Mengesha, B; Rosing, H; Schellens, JH, 2016) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 1.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burza, S | 1 |
| Mahajan, R | 1 |
| Kazmi, S | 1 |
| Alexander, N | 1 |
| Kumar, D | 1 |
| Kumar, V | 1 |
| Lasry, E | 1 |
| Harshana, A | 1 |
| de Lima Pereira, A | 1 |
| Das, P | 1 |
| Verma, N | 1 |
| Das, VNR | 1 |
| Lal, CS | 1 |
| Rewari, B | 1 |
| Goyal, V | 1 |
| Rijal, S | 1 |
| Alves, F | 2 |
| Gill, N | 1 |
| Pandey, K | 1 |
| Adriaensen, W | 1 |
| Cuypers, B | 1 |
| Cordero, CF | 1 |
| Mengasha, B | 1 |
| Blesson, S | 2 |
| Cnops, L | 1 |
| Kaye, PM | 1 |
| Diro, E | 2 |
| van Griensven, J | 1 |
| Kip, AE | 1 |
| Rosing, H | 1 |
| Hillebrand, MJ | 1 |
| Mengesha, B | 1 |
| Hailu, A | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Dorlo, TP | 1 |
| Barragán, P | 1 |
| López-Velez, R | 1 |
| Olmo, M | 1 |
| Podzamczer, D | 1 |
| Vase, MØ | 1 |
| Hellberg, YK | 1 |
| Larsen, CS | 1 |
| Petersen, E | 1 |
| Schaumburg, H | 1 |
| Bendix, K | 1 |
| Ravel, C | 1 |
| Bastien, P | 1 |
| Christensen, M | 1 |
| d'Amore, F | 1 |
3 trials available for miltefosine and HIV
| Article | Year |
|---|---|
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; HIV | 2022 |
Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Endoribonucleases; Female; Gene Expression | 2020 |
Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Topics: Antiprotozoal Agents; Calibration; Chromatography, Liquid; Coinfection; Dried Blood Spot Testing; Dr | 2016 |
2 other studies available for miltefosine and HIV
| Article | Year |
|---|---|
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias | 2010 |
Development of splenic marginal zone lymphoma in a HIV-negative patient with visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Bone Marrow; HIV; HIV Infections; Humans; Immunophenotyping; K | 2012 |